Observational studyLangenbeck's archives of surgery2025
The necessity of prophylactic central lymph node dissection in clinically n0 papillary thyroid carcinoma: perspective from the endemic region.
Observational study in Langenbeck's archives of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05873283 (Is Central Lymph Node Dissection Necessary in Suspected Papillary Thyroid Cancer and Papillary Thyroid Cancer?), which is not on this map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Is Central Lymph Node Dissection Necessary in Suspected Papillary Thyroid Cancer and Papillary Thyroid Cancer?
Who cites it
5 citing papers in PubMed.
- Delphian lymph node metastasis as a marker of extensive nodal involvement in papillary thyroid cancer.BMC surgery · 2026Article
- Clinicopathological predictors of central lymph node metastasis in clinically node-negative papillary thyroid carcinoma: a retrospective cohort analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Association between ultrasound radiomics features and central lymph node metastasis in patients with papillary thyroid carcinoma.American journal of cancer research · 2026Article
- Article
- Thyroid Cancer: Epidemiology, Classification, Risk Factors, Diagnostic and Prognostic Markers, and Current Treatment Strategies.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProphylactic central lymph node dissection (pCND) in papillary thyroid carcinoma (PTC) is still a matter of debate. Therefore, we aimed to identify the factors affecting central lymph node metastasis (CLNM) in patients with clinically node-negative (cN0) PTC.
methodsThis retrospective study included 248 patients with cN0 PTC who underwent total thyroidectomy (TT) or TT + pCND. Clinicopathological associations among CLNM, complication rates and the effect of pCND on staging were assessed. Risk factors (RFs) and the pattern of lymph node metastasis (LNM) in PTC patients were studied via multivariate analysis.
resultsA total of 216 patients underwent pCND, and 58.8% (127/216) had positive CLNM. Male patients, aged < 41 years, and those with lymphatic invasion were identified as RFs for CLNM, with odds ratios of 2.59, 2.26, and 4.09, respectively. Among the 216 patients, 65 (30%) had transient hypoparathyroidism (HPT), and 20 (9.3%) had permanent HPT. Transient recurrent laryngeal nerve (RLN) palsy occurred in 15 (6.9%) patients, and permanent RLN palsy occurred in 3 (1.4%) patients. Over 55 years of age, 46.7% of patients were upstaged according to the American Joint Committee on Cancer (AJCC) TNM staging system, and 14.2% (n = 18) of the 127 patients with CLNM were upgraded according to the American Thyroid Association (ATA) risk stratification system (RSS).
conclusionTaken together, in terms of the high incidence rate of CLNM in cN0 PTC patients; We believe that routine pCND, which can be performed with low morbidity rates, is optimal for cN0 PTC patients during their first treatment, especially for those with RFs for CLNM. CLINICAL TRIALS NUMBER: NCT05873283.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.